Clinical Trial Update: Phase 3 Study of SK-1403 [Phase 3]

View source ↗

Summary

Phase 3 trial update for SK-1403 in secondary hyperparathyroidism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• SK-1403

Snippet

Sponsor: Sanwa Kagaku Kenkyusho Co., Ltd. | Conditions: Secondary Hyperparathyroidism | Phase 3 | Status: COMPLETED